Certerra Revenue and Competitors
Estimated Revenue & Valuation
- Certerra's estimated annual revenue is currently $155k per year.
- Certerra's estimated revenue per employee is $155,000
Employee Data
- Certerra has 1 Employees.
- Certerra grew their employee count by -50% last year.
Certerra's People
Name | Title | Email/Phone |
---|
Certerra Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Certerra?
Certerra Inc. is based on Long Island NY and was founded by scientists from Cold Spring Harbor Laboratory (Cold Spring Harbor, NY) and Massachusetts Institute of Technology (Cambridge, MA) in Spring 2011. Certerra Inc. is a contract research organization (CRO) providing high-content screening in the mouse brain (HCSiMB) for drug discovery in neuroscience. Our goal is to assist pharmaceutical and biotechnology companies to significantly improve predictability from preclinical animal studies to human outcomes in clinical trials. To this end, we have developed a novel drug screening platform that can generate quantitative correlations between data obtained from drug testing in mouse models and data of pharmacological efficacy and safety in humans. Our methods are applicable to the screening of drugs for a broad spectrum of brain disorders, including neurodevelopmental, psychiatric, and neurodegenerative disorders.
keywords:N/AN/A
Total Funding
1
Number of Employees
$155k
Revenue (est)
-50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.4M | 23 | -12% | N/A |
#2 | $5.9M | 42 | 5% | N/A |
#3 | $9.1M | 56 | 8% | N/A |
#4 | $149.7M | 1048 | 1% | N/A |
#5 | $300M | 1064 | N/A | N/A |